Advent Capital Management Biomarin Pharmaceutical Inc Transaction History

Advent Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $337,779 - $409,918	-4,520 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $37,757 - $46,904	520 Added 13.0%	4,520 $396,000
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $287,480 - $524,120	4,000 New	4,000 $304,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $689,204 - $912,201	-8,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $807,712 - $909,192	8,600 New	8,600 $834,000

631

184M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Advent Capital Management , based on Form 13F filings with the SEC.

Stay updated on Advent Capital Management with notifications on news.